Inozyme Pharma (NASDAQ:INZY) Receives Buy Rating from HC Wainwright
Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the stock. Several other research firms have also commented on INZY. Wedbush reaffirmed an “outperform” rating and set a $7.00 […]
Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the stock. Several other research firms have also commented on INZY. Wedbush reaffirmed an “outperform” rating and set a $7.00 […]
